Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Titel:
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Auteur:
Ascierto, Paolo A Del Vecchio, Michele Mandalá, Mario Gogas, Helen Arance, Ana M Dalle, Stephane Cowey, C Lance Schenker, Michael Grob, Jean-Jacques Chiarion-Sileni, Vanna Márquez-Rodas, Iván Butler, Marcus O Maio, Michele Middleton, Mark R de la Cruz-Merino, Luis Arenberger, Petr Atkinson, Victoria Hill, Andrew Fecher, Leslie A Millward, Michael Khushalani, Nikhil I Queirolo, Paola Lobo, Maurice de Pril, Veerle Loffredo, John Larkin, James Weber, Jeffrey